Reduction of CD11b⁺ myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD₂ antibody ch14.18/CHO

References

• Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert Rev Anticancer Ther. 2017;17:369–11. doi:10.1080/14737140.2017.1285230.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Potschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617–1629. doi:10.1016/S1470-2045(18)30578-3.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Fest S, Kunert R, Katinger H, Pistoia V, Michon J, Lewis G, Ladenstein R, Lode HN. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice. Mol Immunol. 2005;42:1311–1319. doi:10.1016/j.molimm.2004.12.018.
   PubMed Web of Science ®Google Scholar
• Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol. 2012;3:91. doi:10.3389/fphar.2012.00091.
   PubMed Web of Science ®Google Scholar
• Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51:144–149.
   PubMed Web of Science ®Google Scholar
• Chen RL, Reynolds CP, Seeger RC. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating. Cancer Immunol Immunother. 2000;48:603–612. doi:10.1007/s002620050008.
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324–1334. doi:10.1056/NEJMoa0911123.
   PubMed Web of Science ®Google Scholar
• Siebert N, Zumpe M, Juttner M, Troschke-Meurer S, Lode HN. PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO. Oncoimmunology. 2017;6:e1343775. doi:10.1080/2162402X.2017.1343775.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L, et al. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis. 2014;5:e1135. doi:10.1038/cddis.2014.109.
   PubMed Web of Science ®Google Scholar
• Carlson LM, Rasmuson A, Idborg H, Segerstrom L, Jakobsson PJ, Sveinbjornsson B, Kogner P. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis. 2013;34:1081–1088. doi:10.1093/carcin/bgt009.
   PubMed Web of Science ®Google Scholar
• Dierckx de Casterlé I, Fevery S, Rutgeerts O, Poosti F, Struyf S, Lenaerts C, Waer M, Billiau AD, Sprangers B, Dierckx de Casterle I, Fevery S, Rutgeerts O, Poosti F, Struyf S, Lenaerts C. Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. Cancer Immunol Immunother. 2018;67:589–603. doi:10.1007/s00262-017-2114-8.
   PubMed Web of Science ®Google Scholar
• Kroesen M, Bull C, Gielen PR, Brok IC, Armandari I, Wassink M, Looman MWG, Boon L, den Brok MH, Hoogerbrugge PM, et al. Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. Oncoimmunology. 2016;5:e1164919. doi:10.1080/2162402X.2016.1164919.
   PubMed Web of Science ®Google Scholar
• Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CWY, Metelitsa LS, Pique-Regi R, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J clini oncol. 2012;30:3525–3532. doi:10.1200/JCO.2011.40.9169.
   PubMed Web of Science ®Google Scholar
• Santilli G, Piotrowska I, Cantilena S, Chayka O, D’Alicarnasso M, Morgenstern DA, Himoudi N, Pearson K, Anderson J, Thrasher AJ, et al. Polyphenon [corrected] E enhances the antitumor immune response in neuroblastoma by inactivating myeloid suppressor cells. Clini Cancer Res. 2013;19:1116–1125. doi:10.1158/1078-0432.CCR-12-2528.
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rebe C, Ghiringhelli F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010;70(8):3052–3061. doi:10.1158/0008-5472.CAN-09-3690.
   PubMed Web of Science ®Google Scholar
• Keyel ME, Reynolds CP. Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics. 2019;13:1–12.
   PubMed Web of Science ®Google Scholar
• Vetsika EK, Koukos A, Myeloid-Derived Suppressor KA. Cells: major figures that shape the immunosuppressive and angiogenic network in cancer. Cells. 2019;8:1647. doi:10.3390/cells8121647.
   PubMed Web of Science ®Google Scholar
• Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer. 2015;112:1501–1509. doi:10.1038/bjc.2015.101.
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116. doi:10.1126/scitranslmed.3006504.
   PubMed Web of Science ®Google Scholar
• Mo X, Zhang H, Preston S, Martin K, Zhou B, Vadalia N, Gamero AM, Soboloff J, Tempera I, Zaidi MR, et al. Interferon-gamma signaling in melanocytes and melanoma cells regulates expression of CTLA-4. Cancer Res. 2018;78:436–450. doi:10.1158/0008-5472.CAN-17-1615.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–4506. doi:10.4049/jimmunol.0802740.
   PubMed Web of Science ®Google Scholar
• Lode HN, Schmidt M, Seidel D, Huebener N, Brackrock D, Bleeke M, Reker D, Brandt S, Mueller H-P, Helm C, et al. Vaccination with anti-idiotyp e antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response. Cancer Immunol Immunother. 2013;62:999–1010. doi:10.1007/s00262-013-1413-y.
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Varki NM, Dolman CS, Gillies SD, Reisfeld RA. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst. 1997;89:1586–1594. doi:10.1093/jnci/89.21.1586.
   PubMed Web of Science ®Google Scholar
• Kawane K, Tanaka H, Kitahara Y, Shimaoka S, Nagata S. Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci USA. 2010;107(45):19432–19437.doi: 10.1073/pnas.1010603107.
   Google Scholar
• McCarthy MK, Procario MC, Twisselmann N, Wilkinson JE, Archambeau AJ, Michele DE, Day SM, Weinberg JB. Proinflammatory effects of interferon gamma in mouse adenovirus 1 myocarditis. J Virol. 2015;89:468–479.
   PubMed Web of Science ®Google Scholar
• Schiller KR, Zillhardt MR, Alley J, Borjesson DL, Beitz AJ, Mauro LJ. Secretion of MCP-1 and other paracrine factors in a novel tumor-bone coculture model. BMC Cancer. 2009;9:45. doi:10.1186/1471-2407-9-45.
   PubMed Web of Science ®Google Scholar
• Woo YD, Koh J, Kang H-R, Kim HY, Chung DH. The invariant natural killer T cell–mediated chemokine X-C motif chemokine ligand 1–X-C motif chemokine receptor 1 axis promotes allergic airway hyperresponsiveness by recruiting CD103+ dendritic cells. J Allergy Clini Immunol. 2018;142:1781–92.e12. doi:10.1016/j.jaci.2017.12.1005.
   PubMed Web of Science ®Google Scholar
• Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203–2206.
   PubMed Web of Science ®Google Scholar